Market Spotlight: Primary Sclerosing Cholangitis

  • ID: 4462141
  • Report
  • 23 pages
  • Datamonitor Healthcare
1 of 3
This Market Spotlight report covers the Primary Sclerosing Cholangitis market, comprising disease background, treatment overview, key pipeline drugs, clinical trials, and a 10-year global disease prevalence forecast.

Key Takeaways
  • The author estimates that in 2016, there were 227,400 prevalent cases of primary sclerosing cholangitis worldwide among adults aged 30 years and older, and forecasts that number to increase to 265,700 prevalent cases by 2025.
  • The majority of industry-sponsored drugs in active clinical development for primary sclerosing cholangitis are in Phase II, with just one drug in Phase III.
  • Therapies in the pipeline for primary sclerosing cholangitis focus on a wide variety of targets. The majority of pipeline drugs in development are administered via the oral route, with a smaller number of drugs being tested in intravenous, subcutaneous, intramuscular, and topical formulations.
  • High impact upcoming events in the primary sclerosing cholangitis space comprise topline Phase II trial results for BTT-1023 and GS-9674.
  • The distribution of clinical trials across Phase I-IV indicates that the majority of trials for primary sclerosing cholangitis have been in the mid-phase of development, with 75% of trials in Phase II, and only 12.5% of trials each in Phase I and Phase III.
  • The UK and the US lead the number of primary sclerosing cholangitis clinical trials globally, with five trials each. Gilead Sciences is the only company with more than one clinical trial in the primary sclerosing cholangitis space. The company has conducted two Phase II trials
Note: Product cover images may vary from those shown
2 of 3
OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND
Subtypes

TREATMENT

EPIDEMIOLOGY

PIPELINE DRUGS

KEY UPCOMING EVENTS

CLINICAL TRIAL LANDSCAPE
Trials by status
Trials by phase

BIBLIOGRAPHY

APPENDIX

List of Figures
Figure 1: Trends in prevalent cases of primary sclerosing cholangitis, 2016-25
Figure 2: Overview of pipeline drugs for primary sclerosing cholangitis in the US
Figure 3: Pipeline drugs for primary sclerosing cholangitis, by company
Figure 4: Pipeline drugs for primary sclerosing cholangitis, by drug type
Figure 5: Pipeline drugs for primary sclerosing cholangitis, by classifications
Figure 6: Key upcoming events in primary sclerosing cholangitis
Figure 7: Clinical trials in primary sclerosing cholangitis
Figure 8: Top 10 drugs for clinical trials in primary sclerosing cholangitis
Figure 9: Top 10 companies for clinical trials in primary sclerosing cholangitis
Figure 10: Trial locations in primary sclerosing cholangitis
Figure 11: Primary sclerosing cholangitis trials status
Figure 12: Primary sclerosing cholangitis trials sponsors, by phase

List of Tables
Table 1: Prevalent cases of primary sclerosing cholangitis, 2016-25
Table 2: Pipeline drugs for primary sclerosing cholangitis in the US
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll